



**PB 91 of 2020**

# **National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2020 (No. 8)**

---

I, THEA CONNOLLY, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, and delegate of the Minister for Health make the following determination.

Dated 28 September 2020

**THEA CONNOLLY**  
Assistant Secretary  
Pricing and PBS Policy Branch  
Technology Assessment and Access Division  
Department of Health

---

---

## Contents

|                              |   |          |
|------------------------------|---|----------|
| 1                            | Name  |          |
| 2                            | Commencement .....  | 1        |
| 3                            | Authority .....   | 1        |
| 4                            | Schedule.....   | 1        |
| <b>Schedule 1—Amendments</b> |   | <b>2</b> |
|                              | <i>National Health (Continued Dispensing - Emergency Measures) Determination 2020</i> | <i>2</i> |

---

## 1 Name

- (1) This instrument is the *National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2020 (No. 8)*.
- (2) This instrument may also be cited as PB 91 of 2020.

## 2 Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information               |                        |              |
|--|------------------------|--------------|
| Column 1                               | Column 2               | Column 3     |
| Provisions                             | Commencement           | Date/Details |
| 1. <i>The whole of this instrument</i> | <i>1 October 2020.</i> |              |

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

## 3 Authority

This instrument is made under subsection 89A(3) of the *National Health Act 1953*.

## 4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.



---

## Schedule 1—Amendments

### *National Health (Continued Dispensing – Emergency Measures) Determination 2020*

**[1] Part 1, Section 1.04, definition for ‘PSA Guidelines’**

*substitute: PSA Guidelines* means the document titled *Guidelines for the Continued Dispensing of eligible prescribed medicines by pharmacists*, issued by the Pharmaceutical Society of Australia.

**[2] Schedule 1, entry for Aflibercept**

*insert as first entry:*

|  |           |
|--|-----------|
| Solution for intravitreal injection 3.6 mg in 90 microlitres (40 mg per mL) pre-filled syringe | Injection |
|--|-----------|

**[3] Schedule 1, after entry for Amino acid formula with vitamins and minerals without phenylalanine in the form Sachets containing oral powder 27.8 g, 30 (PKU Lophlex)**

*insert:*

|   |      |
|---|------|
| Sachets containing oral powder 28 g, 30 (PKU Lophlex) | Oral |
|---|------|

**[4] Schedule 1, after entry for Apixaban in the form Tablet 5 mg**

*insert:*

|             |   |           |
|-------------|---|-----------|
| Apomorphine | Injection containing apomorphine hydrochloride hemihydrate 100 mg in 20 mL                            | Injection |
|             | Solution for subcutaneous injection containing apomorphine hydrochloride 30 mg in 3 mL pre-filled pen | Injection |

**[5] Schedule 1, omit entry for Daclatasvir**

**[6] Schedule 1, omit entry for Danazol**

---

**[7] Schedule 1, entry for Dexamethasone**

*omit:*

|  |           |
|--|-----------|
| Injection containing dexamethasone sodium phosphate equivalent to 4 mg dexamethasone phosphate in 1 mL | Injection |
| Injection containing dexamethasone sodium phosphate equivalent to 8 mg dexamethasone phosphate in 2 mL | Injection |

**[8] Schedule 1, omit entry for Dipyridamole**